Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1140-1149

  Rodríguez, Alejandro ^a   Díaz, Emili ^a   Martín Loeches, Ignacio ^a   Sandiumenge, Alberto ^a   Canadell, Laura ^a   Díaz, Juan J ^b   Figueira, Juan C ^c   Marques, Asunción ^d   Álvarez Lerma, Francisco ^e   Vallés, Jordi ^f   Baladín, Bárbara ^g   García López, Fernando ^h   Suberviola, Borja ⁱ   Zaragoza, Rafael ^j   Trefler, Sandra ^k   Bonastre, Juan ^l   Blanquer, José ^m   Rello, Jordi ^k  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL DE LA RIBERA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^j HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HOSPITAL UNIVERSITARIO LA FE   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Antiviral treatment; Pneumonia; Prognosis

Indexed keywords

OSELTAMIVIR;

2009 H1N1 INFLUENZA; ADULT; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFECT; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PROPENSITY SCORE; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954614859     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq511     Document Type: Article

References (39)

1. WHO. New influenza A (H1N1) virus infections: global surveillance summary, May 2009. Weekly Epidemiological Record 2009; 84: 173-84. http://www.who.int/wer/2009/wer8420/en/index.html (5 June 2009, date last accessed).
2. WHO. Pandemic (H1N1) 2009-update 106. http://www.who.int/csr/don/2010_06_25/en/print.html (25 June 2010, date last accessed).
3. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361: 1925-34.
4. Pérez-Padilla R, de la Rosa-Zamboni D, Ponce de León S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361: 680-9.
5. Rello J, Rodriguez A, Ibañez P et al. Intensive care adult patients with severe respiratory failure caused by influenza A (H1N1)v in Spain. Crit Care 2009; 13: R148.
6. Díaz E, Rodriguez A, Martin-Loeches I et al. Impact of obesity in patients infected with new influenza A (H1N1)v. Chest 2010; doi:10.1378/chest.10-1160.
7. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009; 302: 1872-9.
8. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-44.
9. Creanga AA, Jhonson TF, Graitcer SB et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115: 717-26.
10. Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303: 1517-25.
11. Cao B, Li XW, Mao Y et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361: 2507-17.
12. Falagas ME, Vouloumanou EK, Baskouta E et al. Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents 2010; 35: 421-30.
13. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
14. Vincent JL, Moreno R, Takala J et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707-10.
15. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
16. WHO. CDC protocol of realtime RTPCR for influenza A (H1N1). Geneva: WHO, April 2009. http://www.who.int/csr/resources/publications/swineflu/realtimeptpcr/en/index.html (28 August 2009, date last accessed).
17. Cate TR. Viral pneumonia due to influenza and parainfluenza viruses and adenoviruses. In: Marrie J, ed. Community-Acquired Pneumonia. New York: Kluwer Academic, 2001; 593-616.
18. WHO. WHO guidelines for pharmacologic management of pandemic (H1N1) 2009 influenza and other influenza viruses. Geneva: WHO, 2009.
19. Rodríguez A, Mendia A, Sirvent JM et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 1493-8.
20. Sinclair JC, Cook RJ, Guyatt GH et al. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001; 54: 253-62.
21. Ferrer R, Artigas A, Suarez D et al. Effectiveness of treatments for severe sepsis. A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180: 861-6.
22. Suarez D, Faries DE. Propensity score regression and stratification. In: Faries DE, Leon AC, Haro JM et al., eds. Analysis of Observational Health Care Data Using SAS. Cary: SAS Institute Inc., 2010; 23-50.
23. Echevarría-Zuno S, Mejía-Aranguré JM, Mar-Obeso AJ et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072-9.
24. McLean E, Pebody RG, Campbell C et al. Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. Epidemiol Infect 2010; 138: 1531-41.
25. Carrillo-Santisteve P, Renard-Dubois S, Cheron G et al. 2009 pandemic influenza A (H1N1) outbreak in a complex of schools in Paris, France, June 2009. Euro Surveill 2010; 15: pii=19599.
26. Domínguez-Cherit G, Lapinsky SE, Macias AE et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009; 302: 1880-7.
27. Lee N, Chan PKS, Hui DSC et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492-500.
28. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin 2007; 23: 2961-70.
29. Lee N, Chan PKS, Choi KW et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12: 501-8.
30. Leekha S, Zitterkopf NL, Espy MJ et al. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28: 1071-6.
31. Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-72.
32. Martín-Loeches I, Sánchez-Corral A, Díaz E et al. Community-acquired respiratory co-infection (CARC) in critically ill patients infected with pandemic 2009 influenza A (H1N1) virus infection. Chest 2010; doi:10.1378/chest.1-1396.
33. Power BM, Forbes AM, van Heerden PV et al. Pharmacokinetics of drugs used in critically ill patients. Clin Pharmacokinet 1998; 34: 25-56.
34. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease, and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-73.
35. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsisandseptic shock - does the dose matter? Crit Care 2009;13:214.
36. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-84.
37. McSharry JJ, Weng Q, Brown A et al. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2009; 53: 2375-81.
38. Ariano RE, Sitar DS, Zelenitsky SA et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182: 357-63.
39. Ministerio de Sanidad y Política Social - Subcomité de Vigilancia. Casos Humanos de Gripe por virus pandémico (H1N1) 2009. Informe 01.12.09. http://www.msc.es/profesionales/saludPublica/gripeA/docs/informacionFallecidosH1N1_091201.pdf (3 July 2010, date last accessed).